Intervacc (IVACC.ST) Stock Price
Intervacc Price
Over the last 12 years Intervacc grew revenue by 30.9% annually, reaching 20.09 M SEK. For Intervacc, the net margin of -402.3% is up versus -560.5% a few years ago. The stock trades about 66% above its 52-week low.
Intervacc stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Intervacc over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Intervacc stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Intervacc's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Intervacc Price |
|---|---|
| 9/18/2026 | 1.01 SEK |
| 9/17/2026 | 1.00 SEK |
| 9/16/2026 | 1.00 SEK |
| 9/15/2026 | 1.00 SEK |
| 9/14/2026 | 1.03 SEK |
| 9/11/2026 | 1.02 SEK |
| 9/10/2026 | 1.03 SEK |
| 9/9/2026 | 1.00 SEK |
| 9/8/2026 | 1.03 SEK |
| 9/7/2026 | 1.07 SEK |
| 9/4/2026 | 1.11 SEK |
| 9/3/2026 | 1.13 SEK |
| 9/2/2026 | 1.11 SEK |
| 9/1/2026 | 1.08 SEK |
| 8/31/2026 | 1.06 SEK |
| 8/28/2026 | 1.06 SEK |
| 8/27/2026 | 1.06 SEK |
| 8/26/2026 | 1.08 SEK |
| 8/25/2026 | 1.10 SEK |
| 8/21/2026 | 1.09 SEK |
| 8/20/2026 | 1.10 SEK |
| 8/19/2026 | 1.15 SEK |
| 8/17/2026 | 1.17 SEK |
| 8/14/2026 | 1.20 SEK |
| 8/13/2026 | 1.22 SEK |
| 8/12/2026 | 1.20 SEK |
| 8/11/2026 | 1.21 SEK |
| 8/10/2026 | 1.21 SEK |
| 8/7/2026 | 1.22 SEK |
| 8/6/2026 | 1.25 SEK |
Intervacc Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Intervacc Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM SEK |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM SEK |
| EBITM SEK |
| EBIT MARGIN% |
| NET INCOMEM SEK |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.00 | 55.00 | 48.00 | 35.00 | 12.00 | 4.00 | 5.00 | 9.00 | 8.00 | 11.00 | 20.00 | 21.00 | 30.00 | 121.00 | 166.00 | 291.00 |
| -20.51 | -11.29 | -12.73 | -27.08 | -65.71 | -66.67 | 25.00 | 80.00 | -11.11 | 37.50 | 81.82 | 5.00 | 42.86 | 303.33 | 37.19 | 75.30 |
| 45.16 | 29.09 | 31.25 | 20.00 | 16.67 | 100.00 | 120.00 | 33.33 | -162.50 | -27.27 | -335.00 | -335.00 | -335.00 | -335.00 | -335.00 | -335.00 |
| 28.00 | 16.00 | 15.00 | 7.00 | 2.00 | 4.00 | 6.00 | 3.00 | -13.00 | -3.00 | -67.00 | -70.35 | -100.50 | -405.35 | -556.10 | -974.85 |
| 2.00 | -7.00 | -13.00 | -30.00 | -27.00 | -25.00 | -29.00 | -64.00 | -93.00 | -77.00 | -84.00 | -77.00 | -83.00 | -42.00 | -166.00 | -291.00 |
| 3.23 | -12.73 | -27.08 | -85.71 | -225.00 | -625.00 | -580.00 | -711.11 | -1,162.50 | -700.00 | -420.00 | -366.67 | -276.67 | -34.71 | -100.00 | -100.00 |
| – | -6.00 | -12.00 | -27.00 | -27.00 | -25.00 | -29.00 | -64.00 | -102.00 | -75.00 | -80.00 | -68.00 | -71.00 | -38.00 | – | – |
| – | – | 100.00 | 125.00 | – | -7.41 | 16.00 | 120.69 | 59.38 | -26.47 | 6.67 | -15.00 | 4.41 | -46.48 | – | – |
| 26.94 | 14.79 | 16.14 | 37.67 | 45.17 | 54.12 | 57.75 | 58.13 | 75.74 | 88.28 | 340.81 | 340.81 | 340.81 | 340.81 | 340.81 | 340.81 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Intervacc generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Intervacc retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Intervacc's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Intervacc has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Intervacc's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Intervacc stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Intervacc Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Intervacc business model & stock analysis
Intervacc Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Intervacc historical P/E ratio, EBIT multiple, and P/S ratio
Intervacc annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Intervacc's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Intervacc's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Intervacc's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Intervacc shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Intervacc Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/12/2026 | -0.06SEK | - | 5.40 MSEK | - | 2026 Q3 |
| 8/20/2026 | -0.05SEK | -0.06SEK | 5.00 MSEK | - | 2026 Q2 |
| 5/13/2026 | -0.06SEK | -0.06SEK | 8.60 MSEK | - | 2026 Q1 |
| 2/16/2026 | -0.06SEK | -0.10SEK | 7.60 MSEK | - | 2025 Q4 |
| 11/19/2025 | -0.15SEK | -0.04SEK | 6.20 MSEK | - | 2025 Q3 |
| 8/29/2025 | -0.20SEK | -0.05SEK | 6.30 MSEK | - | 2025 Q2 |
| 2/13/2025 | -0.19SEK | -0.19SEK | 5.00 MSEK | - | 2024 Q4 |
| 11/14/2024 | -0.19SEK | -0.25SEK | 5.00 MSEK | - | 2024 Q3 |
| 8/28/2024 | -0.29SEK | -0.21SEK | 5.00 MSEK | - | 2024 Q2 |
| 11/15/2023 | -0.04SEK | -0.63SEK | 12.00 MSEK | - | 2023 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Intervacc stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Intervacc shareholder structure
| % | Name |
|---|---|
29.67189% | |
2.79674% | |
2.79522% | |
2.71514% | |
2.47140% | |
2.25887% |
Intervacc Beneficial Ownership Filings (SEC 13D/G)
Intervacc Executives and Management Board
12 members · avg. age 54 · 17 % women
Mr. Jonas Sohlman
Chief Executive Officer
2.83 M SEK
Management
Mr. Jan Persson
Chief Financial Officer
Mr. Patrik Hellberg
Chief Information Officer
Mr. Andreas Johansson
Vice President - Supply Chain Management · since 2022
Mr. Andrew Waller
Chief Scientific Officer · since 2020
Board of Directors
Mr. Hakan Bjoerklund
Independent Chairman of the Board
Prof. Jan-Ingmar Flock
Independent Director · since 2023
Ms. Lisen Fredricson
Independent Director
Mr. Lennart Johansson
Independent Director
Ms. Camilla Mccarthy
Independent Director
Mr. Emil Billbaeck (54)
Independent Director
Frequently asked questions about Intervacc
Intervacc AB operates under a unique business model focused on the development and commercialization of innovative vaccines for livestock animals. By leveraging advanced biotechnology and immunology, Intervacc aims to provide effective and safe solutions to prevent and control infectious diseases prevalent in animal populations. Through research, development, and collaboration with industry partners, Intervacc seeks to address key challenges in animal health and contribute to sustainable farming practices. With a strong emphasis on vaccine technology, Intervacc AB is dedicated to improving the well-being and productivity of livestock animals, thereby supporting the agricultural sector's growth and profitability.
Intervacc AB is primarily active in the biotechnology industry.
The main competitors of Intervacc AB in the market include other companies operating in the field of animal health and vaccines. Some of the key competitors of Intervacc AB include Zoetis Inc., Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim, and Virbac. These companies also focus on developing innovative solutions and vaccines for animal diseases.
Intervacc AB is a biotechnology company based in Sweden, specializing in the development and commercialization of vaccines for infectious animal diseases. Founded in 1983, Intervacc has a rich history in the field of animal health and vaccine research. The company's expertise lies in the improvement of vaccine formulas, resulting in effective immunization against diseases such as Strangles and Equine Influenza in horses. With a strong commitment to scientific innovation and animal welfare, Intervacc AB continues to work towards the prevention and control of infectious diseases in animals, ensuring the wellbeing of livestock and pets worldwide.
Intervacc AB, a prominent stock company, has achieved several noteworthy milestones. One such significant accomplishment includes the successful completion of clinical trials for its novel Strangvac® vaccine, designed to combat equine strangles. Furthermore, Intervacc AB obtained a marketing authorization for Strangvac® from the European Medicines Agency, permitting commercialization across the European Union. The company has also secured substantial funding through various partnerships and collaborations, reinforcing its financial stability and promoting further research and development endeavors. With these achievements, Intervacc AB has demonstrated its pioneering efforts in the field of animal health, establishing a strong reputation in the market.
Intervacc AB is primarily present in Sweden, where its headquarters is located. As a biotechnology company, Intervacc AB focuses on the development and commercialization of vaccines for animals. While the company's primary presence is in Sweden, its vaccines have global potential and can benefit regions and countries worldwide. Intervacc AB aims to expand its reach and establish collaborations and partnerships to deliver its innovative animal vaccines across different markets.
Intervacc AB represents values of innovation, dedication, and excellence in the field of biotechnology. The company is committed to developing safe and effective vaccines for both humans and animals. With a focus on preventing infectious diseases, Intervacc AB aims to improve global health and well-being. The corporate philosophy of Intervacc AB revolves around scientific expertise, research-driven development, and collaboration with industry partners. By prioritizing cutting-edge technology, quality assurance, and regulatory compliance, Intervacc AB strives to contribute to the advancement of healthcare.
9 analysts currently rate the Intervacc stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Intervacc to generate revenue of 21.50 M SEK and earnings per share of -0.20 SEK.
Converted at the current exchange rate, the Intervacc share trades at 0.09 EUR (1.01 SEK).
The Intervacc share (IVACC.ST) is listed on 3 stock exchanges, including: Frankfurt (2E9.F), Stockholm (IVACC.ST).
Intervacc AB is a Swedish biotechnology company focused on the development and marketing of vaccines for animals. The company was founded in 2010 and is headquartered in Stockholm, Sweden. The goal of Intervacc AB is to improve the health and well-being of animals by developing and marketing innovative vaccines that help prevent and treat diseases in animals. Intervacc AB specializes in the development of vaccines for animals and offers products for four different market segments: horses, cattle, pigs, and poultry. The product range currently includes four vaccine candidates in various stages of development and marketing. Each vaccine has been specifically developed for a particular animal species and disease. The first vaccine developed by Intervacc AB is Equilis StrepE, a vaccine for horses used to prevent strangles (an upper respiratory tract infection). The company has also developed vaccine candidates for cattle, pigs, and poultry. The cattle vaccine is a vaccine for preventing infections caused by E. coli bacteria, which can lead to serious illnesses in cattle. The pig vaccine is a vaccine for preventing Streptococcus suis, a bacterium that can cause severe illness in pigs. The poultry vaccine is a vaccine designed to protect against infections caused by Campylobacter jejuni, a bacterium that can cause severe gastrointestinal diseases in humans. Currently, Intervacc AB is working on developing new vaccine candidates for other animal species and diseases. The company has an experienced team of biologists, microbiologists, veterinarians, technicians, and other professionals who work closely together to develop vaccines that are safe and effective. The business strategy of Intervacc AB is to establish a strong presence in the animal vaccine market by developing and marketing innovative products that meet the needs of veterinarians, agricultural farms, and other customers. The company works closely with its customers to better understand their needs and ensure that its products meet their requirements. Intervacc AB has also formed strategic partnerships with other companies in the animal health industry to strengthen the distribution of its products and accelerate growth. The company continuously works on improving its technologies and processes to increase the efficiency and quality of its products. Overall, Intervacc AB is an innovative company specializing in the development and marketing of vaccines for animals. The company has developed a wide range of products for different animal species and diseases, and is continuously working on developing new products. With its strong presence in the animal vaccine market and strategic partnerships, Intervacc AB has built a solid foundation for future growth.
The expected revenue of Intervacc is 21.50 M SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Intervacc is -68.40 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Intervacc is currently -5.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Intervacc stock.
The price-to-sales ratio (P/S) of Intervacc is currently 16.01. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Intervacc stock.
The Eulerpool Quality Score for Intervacc is 3/10.
The ISIN of Intervacc is SE0009607252. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Intervacc is A2DP4W. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Intervacc is IVACC.ST. The ticker symbol is used to trade Intervacc shares on the stock exchange.
Intervacc paid dividends every year for the past 0 years.
Intervacc is assigned to the 'Health' sector.
The dividends of Intervacc are distributed in SEK.
Intervacc stock
Intervacc Peer Group
Intervacc Ticker
Intervacc FIGI
All fundamentals and in-depth analysis of Intervacc
Our stock analysis for Intervacc stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intervacc. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.